InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+43.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Martell Christopher, Directeur. Director active across 1 company, notably Candel Therapeutics, Inc.. Cumulatively, 4 reports have been recorded. Split: 2 buys · 0 sell. Total volume traded: €10k. History available since 8 December 2022. The latest transaction was disclosed on 8 December 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations4 total
3,050 shares@ US$1.6850.0% of flowCommon StockSEC:0000899243-23-005523:0
Canonical exit: 8 Mar 2023 (T+90)
3,050 shares@ US$1.6850.0% of flowCommon StockSEC:0001209191-22-060693:0
Canonical exit: 8 Mar 2023 (T+90)
283,514 sharesCommon StockSEC:0000899243-21-031104:0
283,514 sharesCommon StockSEC:0000899243-21-031104
4 of 4 declarations
About Martell Christopher
Christopher Martell is a Director at Candel Therapeutics, Inc. He plays a crucial role in overseeing operations and the company's strategy, contributing to its development and innovation. His expertise in the biopharmaceutical sector is valuable to the board.
